Flputnam Investment Management Co. Sells 177 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Flputnam Investment Management Co. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,594 shares of the company’s stock after selling 177 shares during the quarter. Flputnam Investment Management Co.’s holdings in IDEXX Laboratories were worth $6,861,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the third quarter worth approximately $25,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $31,000. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the third quarter worth approximately $37,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $41,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.9 %

Shares of NASDAQ:IDXX opened at $437.11 on Friday. The company has a market capitalization of $35.55 billion, a PE ratio of 40.97, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a fifty day moving average price of $435.31 and a two-hundred day moving average price of $451.29. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $580.18.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IDXX shares. Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.